ACADVL inhibitors belong to a distinct chemical class that plays a pivotal role in modulating the activity of the ACADVL enzyme. ACADVL, or acyl-CoA dehydrogenase very long chain, is a crucial enzyme involved in the beta-oxidation of fatty acids within cellular mitochondria. This enzymatic process is integral to the conversion of fatty acids into energy, particularly during periods of increased energy demand or fasting. The ACADVL inhibitors act by specifically targeting and impeding the activity of this enzyme, thereby regulating the breakdown of very long-chain fatty acids. This inhibition may have implications in cellular energy metabolism and lipid homeostasis.
The chemical structures of ACADVL inhibitors are designed to interact with the catalytic site of the ACADVL enzyme, disrupting its normal function. This class of inhibitors typically exhibits specificity for ACADVL, avoiding interference with other enzymes involved in fatty acid metabolism. Researchers have focused on elucidating the structural features of these inhibitors to enhance their selectivity and potency. The intricate understanding of the molecular interactions between ACADVL and its inhibitors is crucial for the development of compounds with optimized pharmacological properties.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $184.00 | ||
Inhibits mitochondrial beta-oxidation by blocking carnitine palmitoyltransferase-1 (CPT1). | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $148.00 $496.00 | 3 | |
Inhibits CPT1, reducing long-chain fatty acid uptake into mitochondria, affecting downstream ACADVL. | ||||||
4-Hydroxy-L-phenylglycine | 32462-30-9 | sc-254680A sc-254680 | 5 g 10 g | $82.00 $109.00 | ||
Inhibits CPT1, similar to Etomoxir, potentially reducing substrate availability for ACADVL. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
An endogenous molecule that inhibits CPT1, potentially limiting substrate for ACADVL. | ||||||
Meldonium | 76144-81-5 | sc-207887 | 100 mg | $252.00 | 1 | |
Inhibits carnitine biosynthesis, indirectly reducing long-chain fatty acid transport into mitochondria. | ||||||
Ranolazine | 95635-55-5 | sc-212769 | 1 g | $107.00 | 3 | |
Partially inhibits beta-oxidation, could reduce workload on ACADVL. | ||||||
Trimetazidine Dihydrochloride | 13171-25-0 | sc-220334 | 10 mg | $209.00 | ||
Inhibits long-chain 3-ketoacyl-CoA thiolase, potentially altering ACADVL activity by substrate balance. | ||||||
4-tert-Butylpyridine | 3978-81-2 | sc-238961 | 10 g | $71.00 | ||
Analog of a fatty acid intermediate that can inhibit beta-oxidation enzymes. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Although an anticonvulsant, has been shown to inhibit fatty acid beta-oxidation. | ||||||
Diclofenac acid | 15307-86-5 | sc-357332 sc-357332A | 5 g 25 g | $107.00 $292.00 | 5 | |
While a nonsteroidal anti-inflammatory drug, it is known to affect mitochondrial functions. | ||||||